What Is End-of-Life Care for Signet Ring Cell Carcinoma?
By CRYSTAL BAI •
The short answer: Signet ring cell carcinoma (SRCC) is an aggressive variant of adenocarcinoma most commonly of the stomach and colon. End-of-life care focuses on managing gastric obstruction, peritoneal disease, ascites, pain, and cachexia through specialized palliative and hospice support.
Understanding Signet Ring Cell Carcinoma at End of Life
Signet ring cell carcinoma (SRCC) is an aggressive histological variant of adenocarcinoma, most commonly arising in the stomach (gastric SRCC), colon, and other GI sites. It is associated with diffuse-type gastric cancer, hereditary diffuse gastric cancer (CDH1 mutations), and has a propensity for early peritoneal spread. Advanced SRCC carries a particularly poor prognosis.
Gastric and Peritoneal Symptom Management
Advanced gastric SRCC causes nausea, vomiting, early satiety, malnutrition, and cachexia from gastric outlet obstruction and peritoneal disease. Palliation focuses on managing these symptoms: antiemetics, gastric decompression (NG tube or venting gastrostomy), nutritional support, and ascites management (paracentesis).
Pain and Quality of Life Management
Peritoneal disease causes significant abdominal pain and distension. Opioid analgesics, corticosteroids, and oncologic palliative procedures (palliative gastrectomy in selected patients for symptom relief) may be considered. Goals-of-care conversations should clarify the patient's wishes about invasive vs. comfort-focused management.
Hereditary SRCC and Family Implications
When SRCC arises in the context of hereditary diffuse gastric cancer (CDH1 mutations), there are significant implications for family members — who face up to 80% lifetime risk of gastric cancer. Genetic counseling for at-risk family members should be facilitated even during end-of-life care for the proband.
Frequently Asked Questions
What is signet ring cell carcinoma?
SRCC is an aggressive adenocarcinoma variant most common in the stomach, characterized by early peritoneal spread and poor prognosis.
When should an SRCC patient consider hospice?
Hospice is appropriate when SRCC is progressing despite systemic therapy, prognosis is six months or less, and the focus shifts to comfort and quality of life.
What symptoms are managed at end of life with gastric SRCC?
Key symptoms include nausea, vomiting, early satiety, cachexia, ascites, and abdominal pain from peritoneal disease.
What are the hereditary implications of signet ring cell carcinoma?
When associated with CDH1 mutations (hereditary diffuse gastric cancer), at-risk family members face high gastric cancer risk and should receive genetic counseling.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.